Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 60036. Отображено 100.
05-01-2012 дата публикации

Pyrazolo[1,5-a]pyrimidines for antiviral treatment

Номер: US20120003215A1
Принадлежит: Gilead Sciences Inc

The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

Подробнее
02-02-2012 дата публикации

3-biphenyl-substituted-3-substituted-4-ketolactam and ketolactone and their utilization as pesticide

Номер: US20120028804A1

The present invention relates to novel 3-biphenyl-substituted, 3-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y and Z are as defined in the disclosure, to processes for their preparation, and to their use as pesticides and/or microbicides and/or herbicides.

Подробнее
01-03-2012 дата публикации

Tri-cyclic pyrazolopyridine kinase inhibitors

Номер: US20120053187A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

Подробнее
08-03-2012 дата публикации

Di-azetidinyl diamide as monoacylglycerol lipase inhibitors

Номер: US20120058986A1
Принадлежит: Janssen Pharmaceutica NV

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein Q and Z are defined herein.

Подробнее
08-03-2012 дата публикации

Carbazole and carboline kinase inhibitors

Номер: US20120058988A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof The Formula (I) compounds inhibit tyrosine kinase activity of Jak2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Подробнее
08-03-2012 дата публикации

Diketopyrrolopyrrole polymers for use in organic semiconductor devices

Номер: US20120059140A1
Принадлежит: BASF SE

The present invention relates to polymers comprising one or more (repeating) unit(s) of the formula (I) which are characterized in that Ar 1 and Ar 1 ′ are independently of each other are an annulated (aromatic) heterocyclic ring system, containing at least one thiophene ring, which may be optionally substituted by one, or more groups, and their use as organic semiconductor in organic devices, especially in organic photovoltaics (solar cells) and photodiodes, or in a device containing a diode and/or an organic field effect transistor. The polymers according to the invention have excellent solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.

Подробнее
15-03-2012 дата публикации

Treatment of cancer

Номер: US20120064071A1
Автор: John Ryan
Принадлежит: Cerulean Pharma Inc

Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.

Подробнее
29-03-2012 дата публикации

Hepatitis C Virus Inhibitors

Номер: US20120076755A1
Принадлежит: Enanta Pharmaceuticals Inc

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Подробнее
29-03-2012 дата публикации

Heterocyclic compound and use thereof

Номер: US20120077799A1
Принадлежит: Takeda Pharmaceutical Co Ltd

Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Подробнее
26-04-2012 дата публикации

Diaza-spiro[5.5]undecanes

Номер: US20120101110A1
Принадлежит: Individual

The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

Подробнее
03-05-2012 дата публикации

Trioxane Monomers and Dimers

Номер: US20120108545A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.

Подробнее
03-05-2012 дата публикации

Compounds for the treatment of multi-drug resistant bacterial infections

Номер: US20120108577A1
Принадлежит: AstraZeneca AB

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Подробнее
03-05-2012 дата публикации

N1/n2-lactam acetyl-coa carboxylase inhibitors

Номер: US20120108619A1
Принадлежит: PFIZER INC

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R 1 , R 2 and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Подробнее
10-05-2012 дата публикации

Material for organic electroluminescence device and organic electroluminescence device using the same

Номер: US20120112629A1
Принадлежит: Idemitsu Kosan Co Ltd

Provided are an organic electroluminescence device, which: shows high luminous efficiency; is free of any pixel defect; and has a long lifetime, and a material for an organic electroluminescence device for realizing the device. The material for an organic electroluminescence device is a compound of a specific structure having a π-conjugated heteroacene skeleton crosslinked with a carbon atom, nitrogen atom, or oxygen atom. The organic electroluminescence device has one or more organic thin film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin film layers contains the material for an organic electroluminescence device.

Подробнее
10-05-2012 дата публикации

Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use

Номер: US20120115853A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds defined by formula (I) wherein the groups R 1 and R 2 are defined as in claim 1 , possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

Подробнее
10-05-2012 дата публикации

Porphyrin compounds comprising one or more pyridone moieties

Номер: US20120115901A1
Принадлежит: VENTANA RESEARCH Corp

Various porphyrin compounds comprising one or more pyridone moieties, intermediates thereof, compositions thereof, and, methods of making and using thereof.

Подробнее
17-05-2012 дата публикации

Heterocyclic compounds and uses thereof

Номер: US20120122838A1

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Подробнее
17-05-2012 дата публикации

Tricyclic n-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use

Номер: US20120122852A1
Принадлежит: Sanofi Aventis France

The invention concerns tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R 1 , R 2 and R 3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.

Подробнее
24-05-2012 дата публикации

5,6-dihydro-1h-pyridin-2-one compounds

Номер: US20120130068A1
Принадлежит: Anadys Pharmaceuticals Inc

The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.

Подробнее
31-05-2012 дата публикации

Substituted Esters as Cannabinoid-1 Receptor Modulators

Номер: US20120135975A1
Принадлежит: Merck and Co Inc

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

Подробнее
07-06-2012 дата публикации

Heteroalkyl linked pyrimidine derivatives

Номер: US20120142680A1
Принадлежит: SBio Pte Ltd

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other conditions or disorders associated with kinases.

Подробнее
21-06-2012 дата публикации

Antibiotic compounds

Номер: US20120156295A1
Принадлежит: Piramal Healthcare Ltd

Purified compounds of formula I are described. Compounds include all stereoisomeric forms and all tautomeric forms of the compounds of formula I and pharmaceutically acceptable salts and derivatives. Processes for the production of the antibacterial compounds by fermentation of the microorganism belonging to Streptomyces species (PM0626271/MTCC 5447) and to pharmaceutical compositions containing one or more of the novel compounds as active ingredient and their use in medicines for treatment and prevention of diseases caused by bacterial infections are described.

Подробнее
21-06-2012 дата публикации

Antimicrobial heterocyclic compounds for treatment of bacterial infections

Номер: US20120157434A1
Принадлежит: CSO of MicuRx Pharmaceuticals Inc

The present invention provides heterocyclic compounds of the following formula I: or pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof useful as antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Подробнее
12-07-2012 дата публикации

Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Номер: US20120178736A1
Принадлежит: Individual

Formula I (Ia and Ib) compounds wherein (i) X 1 is N and X 2 is S, (ii) X 1 is CR 7 and X 2 is S, (iii) X 1 is N and X 2 is NR 2 , or (iv) X 1 is CR 7 and X 2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Подробнее
12-07-2012 дата публикации

Rho kinase inhibitors

Номер: US20120178752A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Подробнее
19-07-2012 дата публикации

Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors

Номер: US20120184505A1
Принадлежит: Individual

In its many embodiments, the present invention provides a novel class of pyrimidine analogs as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention also includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the cell cycle checkpoint modulator as well as combinations and pharmaceutical kits. An example cell cycle checkpoint modulator is shown below: formula (I).

Подробнее
02-08-2012 дата публикации

Oxygen linked pyrimidine derivatives

Номер: US20120196855A1
Принадлежит: SBio Pte Ltd

The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

Подробнее
02-08-2012 дата публикации

2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses

Номер: US20120196866A1
Принадлежит: UCB PHARMA SA

The present invention concerns 2-oxo-1-pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Подробнее
16-08-2012 дата публикации

Thieno- and furo-pyrimidine modulators of the histamine h4 receptor

Номер: US20120208793A1
Принадлежит: Individual

Thieno- and furo-pyrimidine compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H 4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as inflammation.

Подробнее
16-08-2012 дата публикации

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Номер: US20120208831A1

The present invention relates to substituted xanthines of general formula wherein R 1 to R 3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Подробнее
16-08-2012 дата публикации

Fluorinated aromatic materials and their use in optoelectronics

Номер: US20120208989A1
Автор: Haoran Sun
Принадлежит: University of South Dakota

Fluorinated aromatic materials, their synthesis and their use in optoelectronics. In some cases, the fluorinated aromatic materials are perfluoroalkylated aromatic materials that may include perfluoropolyether substituents.

Подробнее
23-08-2012 дата публикации

Heteroaryls and uses thereof

Номер: US20120214794A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention provides compounds of formula I-A or I-B: wherein HY, G 1 , G 2 , R 2 , R 12 , W 1 , W 2 , n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Подробнее
30-08-2012 дата публикации

Imidazopyrazine syk inhibitors

Номер: US20120220582A1
Принадлежит: Gilead Connecticut Inc

Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Подробнее
13-09-2012 дата публикации

Organic compound and photovoltaic device comprising the same

Номер: US20120227802A1
Принадлежит: Cryscade Solar Ltd

The present invention provides a organic compound of the general structural formula 1 and photovoltaic device and photovoltaic layer comprising thereof Said organic compound forms rod-like supramolecules and absorbs electromagnetic radiation in at least one predetermined spectral subrange within a wavelength range from 400 to 3000 nm with excitation of electron-hole pairs. The polycyclic core Cor 1 , the bridging group B, and the polycyclic core Cor 2 form a molecular system selected from the list comprising donor-bridge-acceptor-bridge-donor and acceptor-bridge-donor-bridge-acceptor in which a dissociation of excited electron-hole pairs is carried out. A solution of the organic compound or its salt forms a solid photovoltaic layer on a substrate.

Подробнее
13-09-2012 дата публикации

Compound having a substituted anthracene ring structure and pyridoindole ring structure, and organic electroluminescent device

Номер: US20120228598A1
Принадлежит: Hodogaya Chemical Co Ltd

The present invention relates to a compound having a substituted anthracene ring structure and a pyridoindole ring structure, which is represented by the following general formula (1) or the following general formula (2); and an organic electroluminescent device having a pair of electrodes and at least one organic layer interposed therebetween, in which the compound having a substituted anthracene ring structure and a pyridoindole ring structure, which is represented by the following general formula (1) or the following general formula (2), is used as a constituent material of the aforementioned at least one organic layer.

Подробнее
13-09-2012 дата публикации

Quinolizidinone carboxamide m1 receptor positive allosteric modulators

Номер: US20120232076A1
Принадлежит: Individual

The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Подробнее
27-09-2012 дата публикации

Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Номер: US20120245153A1
Принадлежит: VANDERBILT UNIVERSITY

Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and use thereof.

Подробнее
04-10-2012 дата публикации

Thiazole derivatives for the treatment of diseases such as cancer

Номер: US20120252759A1
Принадлежит: Merck Patent GmBH

Compounds of the formula Ia and Ib, in which R 1 , R 1′ , R 2 , R 3 , R 5 , R 6 and R 7 have the meanings indicated in claim 1 , are kinase inhibitors and can be employed, inter alia, for the treatment of tumours.

Подробнее
11-10-2012 дата публикации

Inhibitors of e1 activating enzymes

Номер: US20120258927A1
Принадлежит: Millennium Pharmaceuticals Inc

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

Подробнее
11-10-2012 дата публикации

Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors

Номер: US20120258952A1
Принадлежит: Array Biopharma Inc

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R 1 , R 2 , R 3 , R 4 and R 5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

Подробнее
08-11-2012 дата публикации

Novel cephalosporins useful as antibacterial agents

Номер: US20120283237A1
Принадлежит: PFIZER INC

The present invention provides novel cephalosporin derivatives of formula I, their analogues, their use for the treatment of infections in mammals, pharmaceutical composition containing these novel compounds, and methods for the preparation of these compounds.

Подробнее
15-11-2012 дата публикации

Novel compounds with high therapeutic index

Номер: US20120289471A1
Автор: V. Ravi Chandran
Принадлежит: Signature R&D Holdings LLC

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Подробнее
15-11-2012 дата публикации

3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES

Номер: US20120289474A1
Принадлежит: NYCOMED GMBH

The compounds of Formula (1), in which A, R1, R2, R3 and R5 have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

Подробнее
15-11-2012 дата публикации

Fused pyridine derivatives

Номер: US20120289497A1
Принадлежит: Xuanzhu Pharma Co Ltd

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R 1 , R 2 , R 3 , Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.

Подробнее
22-11-2012 дата публикации

Gabaergic receptor subtype selective ligands and their uses

Номер: US20120295892A1
Принадлежит: UWM Research Foundation Inc

Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

Подробнее
22-11-2012 дата публикации

Azabenzimidazoles as fatty acid synthase inhibitors

Номер: US20120295915A1
Принадлежит: Individual

Disclosed are compounds having Formula (I), wherein R 1 , R 2 , R 3 , R 4 , Ra, Rb, X, Y, m, and n are defined herein and methods of using the same.

Подробнее
29-11-2012 дата публикации

Compound having pyridoindole ring structure having substituted pyridyl group attached thereto, and organic electroluminescence element

Номер: US20120298969A1
Принадлежит: Hodogaya Chemical Co Ltd

The invention relates to a compound having a pyridoindole ring structure having a substituted pyridyl group of formula (1); and to an organic electroluminescent device comprising a pair of electrodes and at least one organic layer interposed between the electrodes, wherein at least one of the organic layer(s) contains the compound: wherein Ar represents a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, or a substituted or unsubstituted condensed polycyclic aromatic group; R1 to R10 may be the same or different from one another and each independently represents a hydrogen atom, a fluorine atom, a cyano group, an alkyl group, or a substituted or unsubstituted aromatic hydrocarbon group; Z represents a 6-membered aromatic heterocyclic ring containing one nitrogen atom; and m and n each independently represents an integer of 1 to 3, provided that n is 1 when m is 2 or 3.

Подробнее
29-11-2012 дата публикации

Pyrrolotriazine kinase inhibitors

Номер: US20120302747A1
Принадлежит: Bristol Myers Squibb Co

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.

Подробнее
06-12-2012 дата публикации

HIV Integrase Inhibitors

Номер: US20120309698A1
Принадлежит: Bristol Myers Squibb Co

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Подробнее
13-12-2012 дата публикации

[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid

Номер: US20120316156A1
Автор: James L. Freddo
Принадлежит: Anadys Pharmaceuticals Inc

The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a [1,2,4]thiadiazine 1,1-dioxide compound.

Подробнее
20-12-2012 дата публикации

Bridged polycyclic compounds

Номер: US20120321590A1
Принадлежит: Anadys Pharmaceuticals Inc

The invention is directed to amides of bicyclic amine compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Подробнее
27-12-2012 дата публикации

Inhibitors of hepatitis c virus ns5b polymerase

Номер: US20120328569A1
Принадлежит: Individual

Disclosed are compounds of formula (I) that are used as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Подробнее
27-12-2012 дата публикации

Novel kinase inhibitors

Номер: US20120329780A1
Принадлежит: Origenis Gmbh

The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

Подробнее
03-01-2013 дата публикации

Aminotriazolopyridines, compositions thereof, and methods of treatment therewith

Номер: US20130005707A1
Принадлежит: Individual

Provided herein are Heteroaryl Compounds of formula (I): wherein R 1 and R 2 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing inflammatory conditions or cancer, and conditions treatable or preventable by inhibition of a kinase or a kinase pathway comprising administering an effective amount of a Heteroaryl Compound to a subject in need thereof.

Подробнее
17-01-2013 дата публикации

New Chemical Entities To Be Used For Wee1 Inhibition For The Treatment Of Cancer

Номер: US20130018045A1
Принадлежит: ABBOTT LABORATORIES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , A, B, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

Подробнее
07-02-2013 дата публикации

Heterocyclic compounds and uses thereof

Номер: US20130035324A1
Принадлежит: INTELLIKINE LLC

Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Подробнее
14-02-2013 дата публикации

Electroluminescent materials comprising fluorene derivatives

Номер: US20130037752A1
Автор: Gene Carl Koch
Принадлежит: Lomox Ltd

OLED compounds of the general structure: B—S-A-S—B in which rod-like nuclei A includes a condensed aromatic ring structure in turn having fluorene ring structures condensed with at least one additional fluorene ring structures wherein the fluorene ring systems provided by the condensed aromatic structure are substituted at the 9-position, and in which the 9-positions of the fluorenes are not susceptible to oxidation.

Подробнее
14-02-2013 дата публикации

PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE

Номер: US20130039906A1
Принадлежит: Genentech Inc

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Подробнее
14-02-2013 дата публикации

Azaindoles as janus kinase inhibitors

Номер: US20130040933A1
Принадлежит: Individual

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.

Подробнее
21-02-2013 дата публикации

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Номер: US20130045973A1
Принадлежит: Evotec OAI AG

Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Подробнее
07-03-2013 дата публикации

Pyrrolobenzodiazepines used to treat proliferative diseases

Номер: US20130059800A1

Pyrrolobenzodiazepine dimers I having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.

Подробнее
07-03-2013 дата публикации

Thiazolyl- and Oxazolyl-Isoquinolinones and Methods for Using Them

Номер: US20130059843A1
Принадлежит: Individual

The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders.

Подробнее
07-03-2013 дата публикации

Synthesis of substituted pyrazoline carboxamidine derivatives

Номер: US20130060041A1

This invention relates to organic chemistry, in particular to processes for the preparation of pyrazoline carboxamidine derivatives of formula (I), known as potent 5-HT6 antagonists. The invention also relates to novel intermediates of these compounds. wherein the symbols have the meanings given in the description.

Подробнее
21-03-2013 дата публикации

5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

Номер: US20130071352A1
Принадлежит: IDENIX PHARMACEUTICALS, INC.

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 6. The method of claim 1 , wherein Uis S.7. The method of claim 1 , wherein Wis S.8. The method of claim 1 , wherein Wis O.9. The method of claim 1 , wherein Wis N.10. The method of claim 1 , wherein U claim 1 , W claim 1 , Xand Xare C claim 1 , and Vand Vare each independently CR.17. The method of claim 1 , wherein u is 1.18. The method of claim 1 , wherein u is 2.26. The method of claim 1 , wherein Ris —C(O)R claim 1 , —C(O)CH(NRR)R claim 1 , —C(O)CH[N(C(O)R)R]R claim 1 , —C(O)CH[N(C(O)OR)R]R claim 1 , or —C(O)CH[N(C(O)NRR)R]R.27. The method of claim 26 , wherein Ris —C(O)CH[N(C(O)OR)R]R.28. The method of claim 1 , wherein Ris —C(O)R claim 1 , —C(O)CH(NRR)R claim 1 , —C(O)CH[N(C(O)R)R]R claim 1 , —C(O)CH[N(C(O)OR)R]R claim 1 , or —C(O)CH[N(C(O)NRR)R]R.29. The method of claim 28 , wherein Ris —C(O)CH[N(C(O)OR)R]R.30. The method of claim 3 , wherein each Ris independently hydrogen or —C(O)OR.31. The method of claim 1 , wherein each Ris independently hydrogen claim 1 , methyl claim 1 , isopropyl claim 1 , 2-methylpropyl claim 1 , 1-methylpropyl claim 1 , 2-methylthioethyl claim 1 , phenyl claim 1 , benzyl claim 1 , 3-indolylmethyl claim 1 , hydroxymethyl claim 1 , 1-hydroxyethyl claim 1 , sulfhydrylmethyl claim 1 , 4-hydroxybenzyl claim 1 , aminocarbonylmethyl claim 1 , 2-(aminocarbonyl)ethyl claim 1 , carboxymethyl claim 1 , 2-carboxyethyl claim 1 , 4-aminobutyl claim 1 , 3-guanidinopropyl claim 1 , or 5-imidazolylmethyl.32. The method of claim 1 , wherein Ris methyl claim 1 , ethyl claim 1 , propyl claim 1 , or butyl.33. The method of claim 1 , wherein Ris hydrogen.34. The method of claim 1 , wherein Rand Rtogether with the C and N atoms to which they ...

Подробнее
21-03-2013 дата публикации

Soluble mtor complexes and modulators thereof

Номер: US20130072485A1

The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one or more of mTORC1, mTORC2, and PI3K-related proteins. Novel methods of providing soluble mTORC1 and mTORC2 complexes are discussed, as well as methods of using the soluble complexes in a high-throughput manner to screen for inhibitory compounds.

Подробнее
21-03-2013 дата публикации

Spirooxazine radical derivatives and reversible isomerization reaction

Номер: US20130072678A1
Автор: Atsumasa Sawada
Принадлежит: NEC Corp

The present invention can provide new spirooxazine radical derivatives of the following general formula (1) which have chromic property enabling the distinction between the radical species and the cation species on the basis of absorption wavelength:

Подробнее
28-03-2013 дата публикации

Kinase protein binding inhibitors

Номер: US20130079297A1

The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.

Подробнее
28-03-2013 дата публикации

BETA-LACTAMASE INHIBITORY COMPOUNDS

Номер: US20130079318A1
Принадлежит: SOUTHERN METHODIST UNIVERSITY

Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided. 3. A pharmaceutical composition comprising a compound of or and a suitable excipient.4. A pharmaceutical combination comprising a compound of or and a second medicament.5. The combination of wherein the second medicament is a beta-lactam antibiotic.6. A pharmaceutical composition comprising the combination of and a suitable excipient.72. A method of inhibition of a beta-lactamase enzyme comprising contacting the enzyme with an effective amount of any of the compounds of of .8. The method of wherein the beta-lactamase enzyme is produced by a beta-lactam resistant bacterial population within the body of a patient.9. A method of treatment of an infection caused by a beta-lactam resistant bacterial strain in a patient claim 7 , comprising administering the compound of or claim 7 , in a dosage claim 7 , at a frequency claim 7 , and for a duration of time sufficient to provide a beneficial effect to the patient.10. The method of further comprising administering an effective amount of a beta-lactam antibiotic to the patient. This application is a divisional of U.S. Ser. No. 12/463,762, filed May 11, 2009, which is a non-provisional utility of U.S. Ser. No. 61/052,922, filed May 13, 2008, the disclosure of which is incorporated herein by reference in its entirety.Beta-lactam antibiotics, as are well known in the art, include the penicillin and cephalosporin classes of compounds, which have been used extensively for decades for the treatment of bacterial infections. However, certain bacterial strains have developed resistance to some or all of the beta-lactam antibiotics available to the physician. In some cases, this resistance is due to the production by the bacterial strain of an enzyme that degrades the antibiotic by ...

Подробнее
28-03-2013 дата публикации

CEPHEM COMPOUND HAVING PSEUDO-CATECHOL GROUP

Номер: US20130079319A1
Принадлежит: Shionogi & Co., Ltd.

A compound of the formula: 2. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein D is a single bond claim 1 , —NH— or —R—NH— claim 1 , Ris a lower alkylene claim 1 , and E is selected from the formulae (1) to (40).3. The compound claim 2 , or an ester claim 2 , a protected compound at the amino on the ring in the 7-side chain claim 2 , a pharmaceutically acceptable salt claim 2 , or a solvate thereof according to claim 2 , wherein D is —NH— claim 2 , —CH—NH— or —CH—CH—NH—.4. The compound claim 3 , or an ester claim 3 , a protected compound at the amino on the ring in the 7-side chain claim 3 , a pharmaceutically acceptable salt claim 3 , or a solvate thereof according to claim 3 , wherein E is a group selected from the formulae (5) claim 3 , (6) claim 3 , (10) claim 3 , (11) claim 3 , (26) claim 3 , (29) to (34) claim 3 , (36) and (37).5. The compound claim 3 , or an ester claim 3 , a protected compound at the amino on the ring in the 7-side chain claim 3 , a pharmaceutically acceptable salt claim 3 , or a solvate thereof according to claim 3 , wherein E is a group of the formula (26) or (31).6. The compound claim 2 , or an ester claim 2 , as protected compound at the amino on the ring in the 7-side chain claim 2 , a pharmaceutically acceptable salt claim 2 , or a solvate thereof according to claim 2 , wherein D is a single bond.7. The compound claim 6 , or an ester claim 6 , a protected compound at the amino on the ring in the 7-side chain claim 6 , a pharmaceutically acceptable salt claim 6 , or a solvate thereof according to claim 6 , wherein E is a group selected from the formulae (1) to (4) claim 6 , (7) claim 6 , (12) to (25) claim 6 , (27) and (28).8. The compound claim 6 , or an ester claim 6 , a protected compound at the amino on the ring in the 7-side chain claim 6 , a pharmaceutically ...

Подробнее
28-03-2013 дата публикации

GYRASE INHIBITORS

Номер: US20130079323A1
Принадлежит: TRIUS THERAPEUTICS, INC.

Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR; Ris H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR, or CRR; Ris H or Calkyl; Rand Rare each independently H or Calkyl; Ris H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; Ris H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein Rand Rtogether may join to form a fused ring; and Ris selected from the group consisting of H, Calkyl, Calkenyl, Calkynyl, halo Calkyl, halo Calkenyl, halo Calkynyl, Chydroxyalkyl, Calkyl chloride, Calkenyl chloride, and Calkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof. 2. The compound of claim 1 , whereinY is N; and{'sub': '2', 'L is O, S, NH, or CH.'}3. The compound of claim 1 , wherein Z is CR claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , halo claim 1 , unsubstituted Calkyl claim 1 , and Calkyl substituted with one or more substituents selected from the group consisting of ═O claim 1 , halo claim 1 , NH claim 1 , NHCH claim 1 , ≡N claim 1 , and Calkenyl claim 1 , wherein Rand Rtogether may join to form a fused ring.4. The compound of claim 1 , wherein Ris methyl claim 1 , C(O)CH claim 1 , C(O)NH claim 1 , CHOH claim 1 , CF claim 1 , CN claim 1 , CHF claim 1 , CHO claim 1 , acetyl claim 1 , Cl or Br.5. The compound of claim 1 , wherein Rcomprises at least one aryl or heteroaryl moiety.6. The compound of claim 1 , wherein the at least one aryl or a heteraryl moiety of Ris directly linked to L.7. The compound of claim 1 , wherein the at least one aryl or heteraryl moiety of Ris substituted ...

Подробнее
28-03-2013 дата публикации

BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF

Номер: US20130079511A1
Принадлежит: WISCONSIN ALUMNI RESEARCH FOUNDATION

The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds are much less developed. The use of bicyclic methylene aziridines (MAs), prepared via intramolecular allene aziridination, as scaffolds for functionalization of all three allene carbons, among other reactions, is described herein. 1. A method comprising forming a bicyclic methylene aziridine by an intramolecular allene aziridination reaction;{'sub': '2', 'wherein an allene group is tethered to an —NHgroup, and the amino group is separated from the proximal allene carbon by 3, 4, 5, or 6 atoms linearly;'}the method comprising combining the allene, an effective rhodium catalyst, a solvent, and an oxidant, to provide a reaction mixture, thereby initiating an intramolecular allene aziridination reaction, to provide a bicyclic methylene aziridine.2. The method of wherein the rhodium catalyst is Rh(esp)where esp is α claim 1 ,α claim 1 ,α′ claim 1 ,α′-tetramethyl-1 claim 1 ,3-benzenedipropionate claim 1 , or Rh(TPA)where TPA is triphenylacetate.3. The method of wherein the oxidant is a hypervalent iodide oxidant or a one-electron cerium or lead oxidant.4. The method of wherein the oxidant is PhIO claim 3 , PhI(OAc) claim 3 , PhI(OPiv) claim 3 , Ce(SO) claim 3 , or Pb(OAc).5. The method of wherein the reaction mixture further comprises a drying agent claim 4 , an acid neutralizing agent claim 4 , or a combination thereof.6. The method wherein the aziridine nitrogen of the bicyclic methylene aziridine is substituted by an electron-withdrawing group.7. The method of wherein the allene is mono-substituted claim 1 , di-substituted claim 1 , tri-substituted claim 1 , or tetra-substituted.9. The method of further comprising contacting the bicyclic methylene aziridine with a nucleophile to provide a nucleophile-addition product.10. The method of ...

Подробнее
04-04-2013 дата публикации

AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY

Номер: US20130085143A1
Принадлежит:

Novel amino acids derivatives, in particular some amino acid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer. 2. The compounds according to in which m=0 or 1 claim 1 , p=0 claim 1 , r=0 and T=H.4. The compounds according to claim 1 , in which W═W═H.5. The compounds according to claim 1 , in which n=0 or 1 and X is H or an optionally substituted aryl or heteroaryl.6. The compounds according to claim 1 , in which X is phenyl.7. The compounds according to claim 1 , in which Y is an -alkylaryl claim 1 , such as —CHaryl claim 1 , where the aryl is optionally substituted by one or more identical or different substituents chosen from halogen claim 1 , OR claim 1 , NRR′ claim 1 , SR claim 1 , alkyl claim 1 , CN claim 1 , perhalogenoalkyl.13. The process according to claim 10 , further comprising the step of isolating the obtained compound.14. A pharmaceutical composition comprising a compound of formula (I) as defined in and a pharmaceutically acceptable carrier.15. The composition according to where said carrier is a cyclodextrin.16. A compound of formula (I) as defined in for inhibiting the Met family.17. A compound of formula (I) as defined in for treating and/or preventing Met family-triggered disorders.18. A compound of formula (I) according to for treating and/or preventing cancer(s) claim 17 , infections diseases and pain.19. A combination of a compound as defined in with one or more agent(s) and/or pharmaceutical composition(s) useful for the treatment and/or prevention of cancer(s) claim 1 , infections diseases and pain.20. A compound of formula (I) as defined in for treating and/or preventing distinct tumours characterised by alteration of selective signals. The present invention is related to novel aminoacids derivatives, pharmaceutical compositions comprising the same, processes for the preparation of said derivatives and uses of said compositions. Particularly, the present invention ...

Подробнее
04-04-2013 дата публикации

THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS

Номер: US20130085155A1
Принадлежит: Sirtris Pharmaceuticals

Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. 110-. (canceled)12. The pharmaceutical composition for topical administration of claim 11 , comprising 0.001 to 10% by weight of the compound.13. The pharmaceutical composition for topical administration of claim 12 , comprising 0.1 to 5% by weight of the compound.14. The pharmaceutical composition for topical administration of claim 11 , comprising 0.25 to 75% by weight of the compound.15. The pharmaceutical composition for topical administration of claim 14 , comprising 0.25 to 30% by weight of the compound.16. The pharmaceutical composition for topical administration of claim 15 , comprising 0.25 to 15% by weight of the compound.17. The pharmaceutical composition for topical administration of claim 16 , comprising 1.0 to 10% by weight of the compound.18. The pharmaceutical composition for topical administration of claim 11 , wherein the topical carrier is selected from water claim 11 , alcohol claim 11 , glycerin claim 11 , mineral oil claim 11 , silicone claim 11 , petroleum jelly claim 11 , lanolin claim 11 , fatty acids claim 11 , vegetable oil claim 11 , paraben claim 11 , and wax.19. The pharmaceutical composition for topical administration of claim 11 , wherein the composition is in a form selected from an ointment claim 11 , a lotion claim 11 , a cream claim 11 , a microemulsion claim ...

Подробнее
11-04-2013 дата публикации

Heteroaryl imidazolone derivatives as jak inhibitors

Номер: US20130089512A1

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Подробнее
11-04-2013 дата публикации

OPTICALLY-DETECTABLE ENZYME SUBSTRATES AND THEIR METHOD OF USE

Номер: US20130090470A1
Принадлежит: LIFE TECHNOLOGIES CORPORATION

The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a β-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a β-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a β-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a β-lactmase or instructions for using the components in an assay. 137-. (canceled) The present application is a continuation of U.S. patent application Ser. No. 12/099,085, filed on Apr. 7, 2008, which is a continuation of U.S. patent application Ser. No. 11/040,924, filed Jan. 21, 2005, which claims priority to U.S. Provisional Patent Application Ser. No. 60/538,357, filed Jan. 21, 2004, the contents of which are hereby incorporated herein by reference in their entirety.1. Field of the InventionThis disclosure relates to enzyme substrates that exhibit a detectable response following a reaction catalyzed by an enzyme. Particular embodiments concern substrates that provide detectable optical responses (such as fluorescence changes) when contacted with a β-lactamase [and/or a related enzymes]. The substrates are useful in a variety of fields, including immunology, diagnostics, drug discovery and molecular biology.2. Background of the InventionAn important mechanism of microbial resistance to β-lactam antibiotics is the production of enzymes known as β-lactamases or cephalosporinases. These enzymes hydrolytically cleave β-lactam antibiotics such as penicillins and cephalosporins. This type of resistance can be transferred horizontally by plasmids that are capable of rapidly spreading the resistance, not only to other members of the same strain of bacteria, ...

Подробнее
18-04-2013 дата публикации

CYSTEINE DERIVATIVE

Номер: US20130095048A1
Принадлежит: AJINOMOTO CO., INC.

Cysteine compounds represented by the following formula 2. A cosmetic composition according to claim 1 , further comprising at least one ingredient selected from the group consisting of an oily component claim 1 , a surfactant claim 1 , an amino acid claim 1 , an amino acid derivative claim 1 , a lower alcohol claim 1 , a polyhydric alcohol claim 1 , a sugar alcohol claim 1 , an alkylene oxide adduct of a sugar alcohol claim 1 , a water-soluble polymer claim 1 , an antimicrobial agent claim 1 , a disinfectant claim 1 , an anti-inflammatory agent claim 1 , an analgesic claim 1 , an antifungal agent claim 1 , a stratum corneum peeling agent claim 1 , a skin colorant claim 1 , a hormone claim 1 , a UV absorber claim 1 , a hair-growth promoter claim 1 , a whitening agent claim 1 , an antiperspirant claim 1 , an astringent active ingredient claim 1 , a perspiration deodorant claim 1 , a vitamin claim 1 , a vasodilator claim 1 , a crude drug claim 1 , a pH adjuster claim 1 , a viscosity modifier claim 1 , a pearly pigment claim 1 , a natural perfume claim 1 , a synthetic perfume claim 1 , a dye claim 1 , an antioxidant claim 1 , a preservative claim 1 , am emulsifier claim 1 , a fat claim 1 , a wax claim 1 , a silicone compound claim 1 , a balm claim 1 , and a mixture thereof.3. A cosmetic composition according to claim 1 , wherein said at least one cysteine compound is one or more compounds selected from the group consisting of N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid claim 1 , N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid 2-ethyl ester claim 1 , and a salt thereof.4. A cosmetic composition according to claim 1 , wherein said at least one cysteine compound is one or more compounds selected from the group consisting of trans N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid claim 1 , trans N-acetyl-2-methylthiazolidine-2 claim 1 ,4-dicarboxylic acid 2-ethyl ester claim 1 , and a salt thereof.6. A cosmetic composition according ...

Подробнее
18-04-2013 дата публикации

Pyridone derivative having integrase inhibitory activity

Номер: US20130096109A1
Принадлежит: Shionogi and Co Ltd

An object of the present invention is to provide a novel integrase inhibitor. The present invention relates to a novel compound having an antiviral effect, more specifically, a pyridone derivative having HIV integrase inhibitory activity, and a medicament containing the same, in particular, an anti-HIV agent. The compound of the present invention has integrase inhibitory activity and/or cell proliferation inhibitory activity against viruses, in particular, HIV and drug-resistant strains thereof. Thus, the compound is useful in preventing or treating various diseases, viral infections (for example, AIDS), and the like in which integrase participates.

Подробнее
18-04-2013 дата публикации

Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction

Номер: US20130096110A1
Принадлежит: VANDERBILT UNIVERSITY

Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction. 2. The method of claim 1 , wherein the mammal is a human.3. The method of claim 1 , wherein the dysfunction is Parkinson's disease.4. The method of claim 1 , wherein the dysfunction is schizophrenia claim 1 , psychosis claim 1 , “schizophrenia-spectrum” disorder claim 1 , depression claim 1 , bipolar disorder claim 1 , cognitive disorder claim 1 , delirium claim 1 , amnestic disorder claim 1 , anxiety disorder claim 1 , attention disorder claim 1 , obesity claim 1 , eating disorder claim 1 , or NMDA receptor-related disorder.5. The method of claim 1 , wherein the dysfunction is Parkinson's disease; anxiety; motor effects after alcohol consumption; neurogenic fate commitment and neuronal survival; epilepsy; or certain cancers claim 1 , for example claim 1 , medulloblastoma claim 1 , inflammation (for example claim 1 , multiple sclerosis) and metabolic disorders (for example claim 1 , diabetes) and taste enhancing associated with glutamatergic dysfunction and diseases in which mGluR4 receptor is involved.6. The method of claim 1 , wherein the mammal has been diagnosed with the dysfunction prior to the administering step.7. The method of claim 1 , further comprising the step of identifying a mammal having a need for treatment of the dysfunction.825-. (canceled)27. The compound of claim 25 , wherein n is 2.28. The compound of claim 25 , wherein X is N claim 25 , S claim 25 , or CR.29. The compound of claim 25 , wherein Y is N claim 25 , or NH.30. The compound of claim 25 , wherein ...

Подробнее
18-04-2013 дата публикации

BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF

Номер: US20130096141A1
Принадлежит:

Compounds of structural formula I: are GPR119 agonists and are useful for the treatment, control or prevention of disorders responsive to agonism of GPR119, such as metabolic-related disorders such as type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia or syndrome X. The compounds are also reported as being useful for controlling weight gain, controlling food intake, and inducing satiety in mammals. 142-. (canceled)44. The compound of claim 43 , wherein A is —O—.47. The compound of claim 43 , wherein W is —C(O)O— or —C(O)—.48. The compound of claim 43 , wherein W is a bond.49. The compound of claim 43 , wherein Ris C-Calkyl claim 43 , haloalkyl claim 43 , heteroaryl or cycloalkyl.50. The compound of claim 43 , wherein Ar is aryl or heteroaryl.51. The compound of claim 43 , wherein Ar is phenyl.52. The compound of claim 43 , wherein Ar is pyridyl.54. The compound of claim 43 , wherein J and M are each —N—.55. The compound of claim 43 , wherein A is —O— and W is —C(O)O— claim 43 , a bond or —CH—.58. A compound of or pharmaceutically acceptable salt thereof claim 57 , wherein X is —S—.59. A compound of or pharmaceutically acceptable salt thereof claim 57 , wherein X is —NC-Calkyl-.61. A pharmaceutical composition comprising a compound of claim 43 , or a pharmaceutically acceptable salt thereof claim 43 , and a pharmaceutically acceptable carrier.62. A method for the treatment of a condition selected from the group consisting of obesity and diabetes comprising administering to an individual a pharmaceutical composition comprising the compound of . The present invention relates to bicyclic heterocycle derivatives, compositions comprising a bicyclic heterocycle derivative, and methods of using the bicyclic heterocycle derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a ...

Подробнее
18-04-2013 дата публикации

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

Номер: US20130096162A1
Принадлежит:

The invention is directed to compounds having the formula: 2. The compound of claim 1 , wherein r is 1.3. (canceled)5. The compound of claim 4 , wherein Ris selected from —COOH claim 4 , —SONHR claim 4 , and tetrazol-5-yl.711-. (canceled)12. The compound of claim 1 , wherein Ris selected from —Calkyl and —Calkylene-O—Calkylene-R claim 1 , where Ris —Calkyl.13. The compound of claim 12 , wherein Ris selected from —Calkyl and —O—Calkyl.14. The compound of claim 1 , wherein X is —Calkylene- claim 1 , 1 to 4-CH-moieties in the alkylene are replaced with a —NR—C(O)— or —C(O)—NR— moiety claim 1 , and Ris selected from H and —OH.15. The compound of wherein X is selected from: —C(O)NH—; —CH—NHC(O)—; —C(O)NH—CH—; —C(O)NH—NHC(O)—; —CH═C(—CH-2-thiophene)-C(O)NH—; —(CH)—NHC(O)—; —C(O)NH—CH—CH(COOH)—CH—; —C(O)NH—CH(benzyl)-CH—NHC(O)—; —C(O)NH—CH(benzyl)-CH—C(O)NH—; —CH—NHC(O)—CH—NHC(O)—; —CH—NHC(O)-cyclohexylene-NHC(O)—; —CH—N(OH)C(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—CH—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—C(O)N(OH)—CH—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; and —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—.16. The compound of claim 15 , wherein X is selected from —C(O)NH— and —CH—NHC(O)—.17. The compound of claim 1 , wherein Ris selected from —Calkylene-SR claim 1 , —Calkylene-C(O)NRR claim 1 , —Calkylene-NR—C(O)R claim 1 , —NH—Calkylene-P(O)(OR) claim 1 , —Calkylene-P(O)ORR claim 1 , —Calkylene-CHR—COOH claim 1 , and —Calkylene-C(O)NR—CHR—COOH; Ris H claim 1 , Ris —OH claim 1 ...

Подробнее
18-04-2013 дата публикации

NOVEL CEPHEM DERIVATIVE

Номер: US20130096299A1
Принадлежит: Shionogi & Co., Ltd.

Provided is a cephem compound which has a wide antimicrobial spectrum, and in particular exhibit potent antimicrobial activity against beta-lactamase producing Gram negative bacteria, and pharmaceutical composition comprising the same. 2. The compound , or an ester , a protected compound at the amino on the ring in the 7-side chain , a pharmaceutically acceptable salt , or a solvate thereof according to , wherein D is a single bond , —NH— , or —R—NH— wherein Ris as defined in .3. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein D is —NH— claim 1 , —CH—NH— claim 1 , or —CH—CH—NH—.4. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein D is a single bond.6. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein E is selected from formulae (1) to (9) claim 1 , (11) to (40) claim 1 , (47) to (49) claim 1 , (51) and (52).7. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein E is selected from formulae (5) claim 1 , (6) claim 1 , (9) to (11) claim 1 , (26) claim 1 , (29) to (34) claim 1 , (36) claim 1 , (37) and (50).8. The compound claim 1 , or an ester claim 1 , a protected compound at the amino on the ring in the 7-side chain claim 1 , a pharmaceutically acceptable salt claim 1 , or a solvate thereof according to claim 1 , wherein E is selected from formulae (5) claim 1 , (6) claim 1 , (10) and (11).9. The compound ...

Подробнее
25-04-2013 дата публикации

Sirtuin activators and activation assays

Номер: US20130102009A1

Provided are methods and compositions for detecting a compound that activates a sirtuin deacetylase activity on a fluorescent-free activation substrate in vitro. Further provided are sirtuin modulating compounds of the formulas (I)-(XXI), and related compounds (XXXI), (XXXII), (XXXIII), and (XXXIV), including the fluorescent free-substrate SIRT1 activator compounds of formulas (XL), (XI), (XII), and (XIII).

Подробнее
25-04-2013 дата публикации

Cephem compound having catechol group

Номер: US20130102583A1
Принадлежит: Shionogi and Co Ltd

A compound of the formula: wherein X is —N═, —CH═, or the like; W is —CH 2 — or the like; U is —S— or the like; R 1 and R 2 are each independently hydrogen, halogen, optionally substituted lower alkyl, or the like; R 3 is hydrogen or the like; each R 4 is independently hydrogen, halogen, or the like; m is an integer from 0 to 2; Q is a single bond, or the like; G is —C(═O)—, or the like; D is a single bond, —NH—, or the like; and E is a cyclic quaternary ammonium group, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.

Подробнее
25-04-2013 дата публикации

Treatment of cancers having k-ras mutations

Номер: US20130102595A1
Принадлежит: Curis Inc

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

Подробнее
25-04-2013 дата публикации

METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE

Номер: US20130102617A1
Принадлежит: Astellas Pharma Inc.

Phenylacetamide compounds of the formula 1. (canceled)2. The method of claim 18 , wherein n is 0.3. The method of claim 2 , wherein Ris methyl claim 2 , trifluoromethyl claim 2 , or cyclopropyl.4. The method of claim 3 , wherein Ris cyclopropyl.6. The method of claim 5 , wherein Ring A is pyrazolyl claim 5 , thiazolyl claim 5 , thiadiazolyl claim 5 , pyridyl or pyrazinyl claim 5 , each of which may be substituted with up to five moieties independently selected from the group consisting of halogen claim 5 , cyano claim 5 , lower alkyl which may be substituted with —OR claim 5 , —OR claim 5 , —O-lower alkylene —OR claim 5 , and —C(O)R.7. The method of claim 6 , wherein [Chem. 21] is a single bond.8. The method of claim 6 , wherein [Chem. 22] is a double bond.9. The method of claim 18 , wherein the compound is selected from the group consisting of:(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-fluoro-1,3-thiazol-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2R)—N-(4-acetyl-1,3-thiazol-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyridin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-[5-(hydroxymethyl)pyrazin-2-yl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)—N-(5-chloropyrazin-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methoxypyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-hydroxycyclopentyl]-N-(5 ...

Подробнее
02-05-2013 дата публикации

MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF

Номер: US20130109656A1
Принадлежит:

This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. 23. The compound of claim 1 , wherein Ris alkyl optionally substituted with OR claim 1 , NRR claim 1 , NRC(═O)(CH)R claim 1 , NRSOR claim 1 , heterocyclyl claim 1 , —OP(═O)(OR) claim 1 , an amino acid residue claim 1 , a dipeptide or a tripeptide claim 1 , or Ris a heterocyclyl.24. The compound of claim 1 , wherein Ris (CH)—OH claim 1 , (CH)—OH claim 1 , (CH)—NH claim 1 , (CH)—NH claim 1 , (CH)—NH claim 1 , (CH)—NHCH(CH) claim 1 , (CH)—NHMe claim 1 , (CH)—NMe claim 1 , (CH)—NMe claim 1 , (CH)—NHMe claim 1 , (CH)NHC(═O)Me claim 1 , (CH)NHC(═O)CH(CH) claim 1 , (CH)NHC(═O)CHCHNMe claim 1 , (CH)NHSOMe claim 1 , (CH)-(pyrrolidin-1-yl) claim 1 , (CH)-(piperidin-1-yl) claim 1 , (CH)-(4-methylpiperidin-1-yl) claim 1 , (CH)-(morpholin-4-yl) claim 1 , (CH)-(pyrrolidin-2-yl) claim 1 , (CH)NH(C═O)CH(Me)NH(C═O)CH(Me)NH claim 1 , (CH)—OPOH claim 1 , CH—O—CHOMe or piperidin-4-yl.25. The compound of claim 1 , wherein Ris (CH)—NH.26. The compound of claim 1 , wherein Ris Z—NR—C(═NR)R claim 1 , Z—NR—C(═NR)NRR claim 1 , Z—C(═NR)NRR claim 1 , Z—O—NRC(═NR)NRR claim 1 , Z—O—NR claim 1 , —C(═NR)R claim 1 , Z—NR—NR—C(═NR)R claim 1 , or Z—NR—NR—C(═NR)NRR.27. The compound of claim 1 , wherein Aris phenyl optionally substituted with one or more groups independently selected from halogen claim 1 , alkyl claim 1 , —ORor —NROR; or Aris a heteroaryl selected from thiophenyl or pyridyl claim 1 , wherein said pyridyl is optionally substituted independently with one or more halogen.28. The compound of claim 1 , wherein Aris phenyl claim 1 , 2 claim 1 ,4-difluorophenyl claim 1 , 2-fluorophenyl claim 1 , 3-fluorophenyl claim 1 , 2-chlorophenyl claim 1 , 3- ...

Подробнее
02-05-2013 дата публикации

Small Molecule Inhibitors of Functions of the HIV-1 Matrix Protein

Номер: US20130109698A1
Автор: Simon Cocklin
Принадлежит: Simon Cocklin

The present invention includes a method of inhibiting, suppressing or preventing retroviral infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising one or more of the compounds of the invention.

Подробнее
02-05-2013 дата публикации

PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS

Номер: US20130109852A1
Принадлежит: Genentech, Inc.

The invention provides processes of preparing, separating, and purifying PI3K inhibitor, Formula I and II compounds, and novel intermediates for preparing Formula I and II compounds. 1. The compound selected from 14 and 14A This application is a divisional of U.S. Ser. No. 12/739,434 filed 29 Jul. 2010, which is a National Stage Application under 35 U.S.C. §371 and claims the benefit of priority to International Application No. PCT/US2008/081204 filed on 24 Oct. 2008, which claims the benefit under 35 USC §119(e) of U.S. Provisional Application Ser. No. 60/982,562 filed on 25 Oct. 2007, each of which are incorporated by reference in entirety.The invention relates generally to processes for making and purifying thienopyrimidine compounds with anti-cancer activity and more specifically to compounds which inhibit PI3 kinase activity.Phosphatidylinositol (hereinafter abbreviated as “PI”) is one of a number of phospholipids found in cell membranes. In recent years it has become clear that PI plays an important role in intracellular signal transduction. Cell signaling via 3′-phosphorylated phosphoinositides has been implicated in a variety of cellular processes, e.g., malignant transformation, growth factor signaling, inflammation, and immunity (Rameh et al (1999) J. Biol Chem, 274:8347-8350). The enzyme responsible for generating these phosphorylated signaling products, phosphatidylinositol 3-kinase (also referred to as PI 3-kinase or PI3K), was originally identified as an activity associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylate phosphatidylinositol (PI) and its phosphorylated derivatives at the 3′-hydroxyl of the inositol ring (Panayotou et al (1992) Trends Cell Biol 2:358-60).Phosphoinositide 3-kinases (PI3K) are lipid kinases that phosphorylate lipids at the 3-hydroxyl residue of an inositol ring (Whitman et al (1988) Nature, 332:664). The 3-phosphorylated phospholipids (PIP3s) generated by PI3-kinases act as second ...

Подробнее
09-05-2013 дата публикации

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

Номер: US20130116233A1
Принадлежит:

The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 3. The compound of claim 1 , where Xis selected from O claim 1 , S claim 1 , —X═C(R)— claim 1 , where C(R) is bound to the carbon atom which carries R.4. The compound of claim 1 , where A is selected from A claim 1 , A claim 1 , Aand A.5. The compound of claim 1 , where Xis C—R.6. The compound of claim 5 , where Ris hydrogen or Y-Cyc.7. The compound of claim 1 , where Xis N.8. The compound of claim 1 , where Xis CH.9. The compound of claim 1 , where Xis S.10. The compound of claim 1 , where Xis O.11. The compound of claim 1 , where Xis C(R)═C(R).12. The compound of claim 1 , where Xis N═(CR).13. The compound of claim 11 , where Ris hydrogen or Y-Cyc3.14. The compound of claim 1 , where Xis N═C(R).15. The compound of claim 11 , where Ris hydrogen.16. The compound of claim 1 , where Ris a radical Y-Cyc.17. The compound of claim 1 , where Ris selected from the group consisting of hydrogen claim 1 , fluorine claim 1 , C-C-alkyl claim 1 , C-C-fluoroalkyl claim 1 , C-C-alkoxy claim 1 , C-C-fluoroalkoxy claim 1 , cyclopropyl claim 1 , optionally substituted by 1 claim 1 , 2 or 3 methyl groups claim 1 , and fluorinated cyclopropyl.18. The compound of claim 17 , where Ris hydrogen.19. The compound of claim 1 , where A is A.20. The compound of claim 19 , where R claim 19 , Rare selected from hydrogen and fluorine.21. The compound of claim 19 , where Rand Rare claim 19 , independently of each other claim 19 , selected from the group consisting of hydrogen claim 19 , fluorine and methyl.22. The compound of claim 1 , where A is A.23. The compound of claim 1 , where A is ...

Подробнее
09-05-2013 дата публикации

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS

Номер: US20130116235A1
Принадлежит: Genentech, Inc.

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 2. The compound of wherein Xis N.3. The compound of wherein Xis N.4. The compound of wherein Xis N.5. The compound of wherein Xand Xare N claim 1 , Xand Xare N claim 1 , or Xand Xare N.6. The compound of wherein Ris optionally substituted C-Cheteroaryl selected from pyrazolyl claim 1 , pyridinyl claim 1 , pyrimidinyl claim 1 , 5-methyl-4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydropyrazolo[1 claim 1 ,5-a]pyrazin-2-yl claim 1 , 5-acetyl-4 claim 1 ,5 claim 1 ,6 claim 1 ,7-tetrahydropyrazolo[1 claim 1 ,5-a]pyrazin-2-yl claim 1 , 6 claim 1 ,7-dihydro-4H-pyrazolo[5 claim 1 ,1-c][1 claim 1 ,4]oxazin-2-yl claim 1 , and 1-methyl-5-(5-(4-methylpiperazin-1-yl)pyridin-2-yl.7. The compound of wherein Ris —(C-Cheteroaryl)-(C-Cheterocyclyl) where heteroaryl is optionally substituted pyridinyl and heterocyclyl is optionally substituted piperazinyl.8. The compound of wherein Ris phenyl claim 1 , optionally substituted with one or more groups selected from F claim 1 , Cl claim 1 , —CH claim 1 , —S(O)CH claim 1 , cyclopropyl claim 1 , azetidinyl claim 1 , oxetanyl claim 1 , and morpholino.11. The compound of wherein Ris CH.12. The compound of wherein Yis CH and Yis N.13. The compound of wherein Yis N and Yis CH.14. The compound of wherein Yand Yare each CH.15. The compound of wherein Yand Yare each CH claim 1 , and Ris CH.16. The compound of selected from Table 1.17. The compound of selected from Table 218. A pharmaceutical composition comprised of a compound of and a pharmaceutically ...

Подробнее
09-05-2013 дата публикации

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

Номер: US20130116430A1
Принадлежит: FUJIFILM Corporation

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein Rrepresents a halogen atom; Rrepresents a Calkyl group, a Calkenyl group, a Calkynyl group, a Ccycloalkyl group, an aryl group, an ar-Calkyl group or a heterocyclic group, each optionally having at least one substituent; Rrepresents an aryl group or a heterocyclic group each optionally having at least one substituent; and Rand Reach independently represent a hydrogen atom; and Rand Rmay form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof. 2. The nicotinamide derivative or a salt thereof according to claim 1 , wherein the substituent optionally possessed by the Calkyl group claim 1 , Calkenyl group claim 1 , Calkynyl group claim 1 , Ccycloalkyl group claim 1 , aryl group claim 1 , ar-Calkyl group or heterocyclic group claim 1 , represented by R claim 1 , is selected from the following substituent group α claim 1 , wherein{'sub': 1-1', '1-6', '2-6', '2-6', '3-8', '1-6', '1-6', '1-6', '2-6', '2-6', '3-8', '1-6', '1-6', '2-6', '2-6', '1-12', '2-12', '2-12', '3-8', '1-6', '1-6, 'sup': 1', '2', '6', '7', '6', '7', '6', '7', '1', '2', '7', '7', '29', '29, 'the substituent group αconsists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a Calkyl group optionally having at least one substituent; a Calkenyl group optionally having at least one substituent; a Calkynyl group optionally having at least one substituent; a Ccycloalkyl group optionally having at least one ...

Подробнее
16-05-2013 дата публикации

Herbicidal Isoxazolo[5,4-B]pyridines

Номер: US20130123105A1
Принадлежит: BASF SE

The invention relates to isoxazolo[5,4-b]pyridine compounds of formula I, 116-. (canceled)18. The method as claimed in claim 17 , wherein in formula I{'sup': '1', 'sub': 1', '6', '1', '6, 'Ris hydrogen, halogen, C-C-alkyl, or C-C-haloalkyl.'}19. The method as claimed in claim 17 , wherein in formula I{'sup': '2', 'sub': 1', '6', '1', '6', '1', '6', '3', '6', '3', '6', '2', '6', '2', '6, 'Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-hydroxyalkyl, C-C-cycloalkyl, C-C-halocycloalkyl, C-C-alkenyl, or C-C-alkynyl.'}20. The method as claimed in claim 17 , wherein in formula I{'sup': '1', 'Ris hydrogen;'}{'sup': '2', 'sub': 1', '6', '1', '6', '1', '6', '3', '6', '3', '6', '2', '6', '2', '6, 'Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-hydroxyalkyl, C-C-cycloalkyl, C-C-halocycloalkyl, C-C-alkenyl, or C-C-alkynyl;'}{'sup': 3', '3, 'sub': 1', '6', '1', '6', '3', '6', '1', '6', '3', '6', '1', '6', '3', '6', '3', '6', '1', '4', '3', '6', '1', '6', '1', '6', '1', '4', '1', '4', '1', '4', '1', '4', '3', '6', '2', '6', '2', '6', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Ris C-C-alkyl, C-C-haloalkyl, C-C-cycloalkyl-C-C-alkyl, C-C-halocycloalkyl-C-C-alkyl, C-C-cycloalkyl, C-C-halocycloalkyl, C-C-alkyl-C-C-cycloalkyl, C-C-alkoxy, C-C-haloalkoxy, or phenyl; wherein the phenyl moieties of Rcan be unsubstituted or substituted with one or more radicals selected from the group consisting of halogen, hydroxy, nitro, cyano, C-C-alkyl, C-C-haloalkyl, C-C-alkoxy-C-C-alkyl, C-C-cycloalkyl, C-C-alkenyl, C-C-alkynyl, C-C-alkoxy, C-C-haloalkoxy, C-C-alkoxycarbonyl, C-C-alkylsulfinyl, C-C-alkylsulfonyl, amino, C-C-alkylamino, N,N-di-(C-C)-alkylamino, heterocyclyl, or phenyl;'}{'sup': 4', '5, 'X is ORor SR.'}21. The method as claimed in claim 17 , wherein in formula I{'sup': '4', 'X is OR;'}{'sup': '4', 'sub': 1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '2', '6', '2', '6', '2', '6, 'Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-cyanoalkyl, C-C- ...

Подробнее
16-05-2013 дата публикации

Tricyclic Compounds and Methods of Making and Using Same

Номер: US20130123235A1
Принадлежит: Individual

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Подробнее
23-05-2013 дата публикации

SPIROXAZOLIDINONE COMPOUNDS

Номер: US20130131042A1
Принадлежит: Merck Sharp & Dohme Corp.

Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety. 2. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein at each occurrence of Ra claim 1 , Ra is hydrogen.3. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris phenyl.4. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris pyridine.5. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris substituted with OH claim 1 , —C-Calkyl claim 1 , —COOH claim 1 , COO—C-Calkyl claim 1 , —O—C-Calkyl —C-Ccycloalkyl claim 1 , —CON(C-Calkyl)NH(C-Calkyl) or heterocycle claim 1 , wherein the —C-Calkyl claim 1 , —C-Ccycloalkyl or —OC-Calkyl is unsubstituted or substituted with 1-4 substituents selected from the group consisting of halogen and —COOH.6. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris imidazole claim 1 , naphthalene claim 1 , phenyl claim 1 , pyridine claim 1 , benzimidazole claim 1 , indole claim 1 , oxazole claim 1 , thiazole claim 1 , benzofuran claim 1 , benzocyclopentane claim 1 , benzotetrahydropyran or pyrazole.7. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris phenyl.8. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris pyridine.9. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris imidazole.10. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris substituted with two substituents independently selected from α.11. A compound of or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris substituted with three substituents ...

Подробнее
23-05-2013 дата публикации

COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Номер: US20130131049A1
Автор: Wu Yong-Jin
Принадлежит:

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: 2. The compound of claim 1 , wherein:{'sub': 1', '2', '3', '4', '5', '6', '1', '6', '1', '6, 'R, R, R, R, R, and Rare independently hydrogen, C-Calkyl or C-Ccycloalkyl;'}{'sub': 1-4', '1-4', '1-4', '1', '6', '1', '6', '2', '4, 'Y is phenyl or thiophenyl and Z is a pyridyl, pyrimidinyl or pyrazinyl, wherein each Y and Z group can be optionally substituted with from 0-3 substituents selected from hydrogen, halogen, amino, Calkylamino, Cdialkylamino, haloCalkyl, OH, CN, C-Calkyl or cycloalkyl, C-Calkoxy, or C-Calkynyl;'}L is either a bond or is —NHCO—; andm is 1 or 2.3. The compound of claim 2 , wherein:{'sub': 1', '2', '3', '4', '5', '6, 'R, R, R, R, R, and Rare hydrogen;'}{'sub': 2', '4, 'Y is phenyl and Z is a pyridyl, wherein each Y and Z group can be optionally substituted with from 0-3 halogen substituents and Z can be optionally substituted with from 0-3 halogen, cyano, or C-Calkynyl substituents;'}L is either a bond or is —NHCO—; andm is 1 or 2.4. The compound of claim 2 , wherein:{'sub': 1', '2', '3', '4', '5', '6, 'R, R, R, R, R, and Rare hydrogen;'}{'sub': 2', '4, 'Y is phenyl optionally substituted with from 0-3 halogen, cyano, or C-Calkynyl substituents;'}L and Z together can be absent; andm is 1 or 2.5. A compound of any claims of 1 to 3 claim 2 , wherein the configuration of the chiral center adjacent to the nitrogen of the aminothiazine is (R) or a pharmaceutically acceptable salt thereof.6. The compound of claim 4 , which is selected from the group consisting of:N-(3-((4aR,7aR)-2-amino-4-a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-chloropicolinamide;N-(3-((4aR,7aR)-2-amino-4-a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3]thiazin-7a-yl)-4-cyanophenyl)-5-chloropicolinamide;N-(3-((4aR,7aR)-2-amino-4-a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3]thiazin-7a-yl)-4-cyanophenyl)-5-bromopicolinamide;N-(3-((4aR,7aR)-2-amino-4a,5,6,7a-tetrahydro-4H- ...

Подробнее
23-05-2013 дата публикации

FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF

Номер: US20130131050A1
Принадлежит: Takeda Pharmaceutical Company Limited

The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. 2. The compound or salt of claim 1 , wherein{'sup': '2', 'Xis 0; and'}{'sup': '4', 'sub': '1-6', 'Ris a Calkyl group optionally substituted by 1 to 3 halogen atoms.'}6. 2-(2 claim 1 ,2 claim 1 ,2-Trifluoroethoxy)-3-[4-(2 claim 1 ,2 claim 1 ,2-trifluoroethoxy)phenyl]-5 claim 1 ,6-dihydropyrido[2 claim 1 ,3-d]pyrimidine-4 claim 1 ,7(3H claim 1 ,8H)-dione or a salt thereof.7. 2-Ethoxy-3-[4-(2 claim 1 ,2 claim 1 ,2-trifluoroethoxy)phenyl]-5 claim 1 ,6-dihydropyrido[2 claim 1 ,3-d]pyrimidine-4 claim 1 ,7(3H claim 1 ,8H)-dione or a salt thereof.8. 3-[4-(2 claim 1 ,2 claim 1 ,2-Trifluoroethoxy)phenyl]-2-(3 claim 1 ,3 claim 1 ,3-trifluoropropyl)-5 claim 1 ,6-dihydropyrido[2 claim 1 ,3-d]pyrimidine-4 claim 1 ,7(3H claim 1 ,8H)-dione or a salt thereof.9. A medicament comprising the compound or salt of .10. The medicament of claim 9 , which is a delta-5-desaturase inhibitor.11. The medicament of claim 9 , which is an agent for the prophylaxis or treatment of eicosanoid-associated diseases.12. The medicament of claim 9 , which is an agent for the prophylaxis or treatment of arteriosclerosis.13. The medicament of claim 9 , which is an agent for the prophylaxis or treatment of diabetes or obesity.14. A method for the prophylaxis or treatment of arteriosclerosis in a mammal claim 1 , comprising administering an effective amount of the compound or salt of to the mammal.15. A method for the prophylaxis or treatment of diabetes or obesity in a mammal claim 1 , comprising administering an effective amount of the compound or salt of to the mammal.1617-. (canceled)18. The compound or salt of for use in the prophylaxis or treatment of ...

Подробнее
23-05-2013 дата публикации

COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Номер: US20130131051A1
Принадлежит:

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: 2. The compound of claim 1 , wherein:{'sub': '2', 'X is selected from CHand O;'}m=0 or 1;n=0 to 3;{'sup': '1', 'sub': 1-4', '1-4', '1-4', '1', '6', '1', '6', '2', '4, 'Rat each instance is selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, or C-Calkynyl;'}L is either a bond or is —NHCO—;{'sub': 1-4', '1-4', '1-4', '1', '6', '1', '6', '2', '4, 'Z is a phenyl, pyridyl, pyrimidinyl, or pyrazinyl group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, Calkylamino, Cdialkylamino, haloCalkyl, CN, C-Calkyl or cycloalkyl, C-Calkoxy, and C-Calkynyl;'}{'sup': 3', '4', '5, 'sub': '1-4', 'and R, Rand Rare independently selected from hydrogen or Calkyl.'}3. The compound of claim 2 , wherein:{'sub': '2', 'X is selected from CHand O;'}m=0 or 1;n=0 to 3;{'sup': '1', 'Rat each instance is selected from halogen,'}L is either a bond or is —NHCO—;{'sub': 2', '4, 'Z is a phenyl, pyridyl, pyrimidinyl, or pyrazinyl group which can be further substituted with from 0-3 substituents selected from halogen, CN, or C-Calkynyl;'}{'sup': '3', 'sub': '1-4', 'Ris selected from hydrogen or Calkyl;'}{'sup': 4', '5, 'and Rand Rare hydrogen.'}4. A compound of any claims of 1 to 3 wherein the configuration of the chiral center adjacent to the nitrogen of the aminothiazine is (S) or a pharmaceutically acceptable salt thereof.5. The compound of claim 4 , which is 5-Chloro-pyridine-2-carboxylic acid ((4aS claim 4 ,11bS)-2-amino-11b-methyl-4 claim 4 ,4a claim 4 ,5 claim 4 ,6 claim 4 ,7 claim 4 ,11b-hexahydro-3-thia-1-aza-dibenzo[a claim 4 ,c]cyclohepten-10-yl)-amide.6. A pharmaceutical composition which comprises one or more of the compounds as claimed in claim 1 , together with one or more pharmaceutically acceptable carriers claim 1 , excipients or diluents.7. A ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
06-06-2013 дата публикации

CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE

Номер: US20130143862A1
Принадлежит:

Provided are compounds of Formula I: 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein m is 0.3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein m is 1.4. The compound of claim 3 , wherein Rand Rare each hydrogen.5. The compound of any one of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rare each Calkyl.6. The compound of claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , wherein Rand Rare each methyl.7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Rand Rtogether with the carbon atom to which they are bound form a group selected from Ccycloalkyl claim 1 , Ccycloalkenyl claim 1 , 3-8 membered heterocycloalkyl and 3-8 membered heterocycloalkenyl claim 1 , each optionally substituted with 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 substituents selected from halogen claim 1 , CN claim 1 , oxo claim 1 , OR claim 1 , OC(O)R claim 1 , OC(O)OR claim 1 , NRR claim 1 , C(O)R claim 1 , C(O)OR claim 1 , C(O)NRR claim 1 , S(O)R claim 1 , SOR claim 1 , SONRR claim 1 , Calkyl and Chaloalkyl.8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein Rand Rtogether with the carbon atom to which they are bound form Ccycloalkyl optionally substituted with 1 claim 7 , 2 claim 7 , 3 claim 7 , 4 or 5 substituents selected from halogen claim 7 , CN claim 7 , oxo claim 7 , OR claim 7 , OC(O)R claim 7 , OC(O)OR claim 7 , NRR claim 7 , C(O)R claim 7 , C(O)OR claim 7 , C(O)NRR claim 7 , S(O)R claim 7 , SOR claim 7 , SONRR claim 7 , Calkyl and Chaloalkyl.9. The compound of claim 8 , or a pharmaceutically acceptable salt thereof claim 8 , wherein Rand Rtogether with the carbon atom to which they are bound form a group selected from cyclopropyl claim 8 , cyclobutyl claim 8 , cyclopentyl and cyclohexyl claim 8 , each optionally substituted with 1 claim 8 , 2 claim 8 , 3 claim 8 , 4 or 5 ...

Подробнее
06-06-2013 дата публикации

NOVEL COMPOUNDS

Номер: US20130143870A1
Принадлежит:

This invention relates to compounds of formula I 3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant claim 1 , diluent and/or carrier.4. A method of treating schizophrenia claim 1 , schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses claim 1 , post stroke dementia claim 1 , deficits in concentration claim 1 , mild cognitive impairment claim 1 , the cognitive dysfunction in Alzheimers disease or the cognitive dysfunction of schizophrenia comprising administering to a patient a therapeutically effective amount of a compound according to . This invention relates to substituted pyrazoles and their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment.Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in many physiological processes, such as synaptic plasticity, long term potentiation involved in both learning and memory as well as sensory perception (Riedel et al., Behav. Brain Res. 2003, 140:1-47). Furthermore, it has been demonstrated that an imbalance of glutamate neurotransmission plays a critical role in the pathophysiology of various neurological and psychiatric diseases.The excitatory neurotransmission of glutamate is mediated through at least two different classes of receptors, the ionotropic glutamate receptors (NMDA, AMPA and kainate) and the metabotropic glutamate receptors (mGluR). The ...

Подробнее